GleamWall
中文EN

SHPH Shuttle Pharmaceuticals Holdings, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1757499 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY15.5%
TTM EPS YoY158.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-90.1%
ROA-72.5%
ROIC (approx.)-99.2%
Asset turnover—

Leverage & solvency

Liabilities / assets15.9%
Debt / equity0.00x
Current ratio0.11x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-26.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$4.05M$3.62M
SG&A expense$5.67M$1.39M
Operating income-$11.92M-$7.70M
Pretax income$11.43M$9.14M
Net income-$11.72M-$9.14M
EBITDA-$11.63M-$7.69M
EPS (basic)-7.16-79.65
EPS (diluted)-7.16-82.60
Weighted avg. shares (diluted)1.64M115,493
Banking
Net interest income—$100,000
Balance sheet
Cash & equivalents$334,005$1.92M
Current assets$502,911$2.21M
PP&E, net$17,319$19,364
Intangibles$9.84M—
Total assets$10.48M$2.51M
Current liabilities$7.97M$1.53M
Total liabilities$8.22M$1.80M
Shareholders' equity$2.25M$709,152
Shares outstanding202,362163,093
Cash flow statement
Operating cash flow-$9.48M-$7.33M
Investing cash flow-$3.06M$2.92M
Financing cash flow$10.95M$3.76M
Depreciation & amortization$290,107$5,463
Stock-based compensation$932,967$259,744

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.